Improved prediction of inhibitor development in previously untreated patients with severe haemophilia A
- 11 December 2014
- journal article
- Published by Wiley in Haemophilia
- Vol. 21 (2), 227-233
- https://doi.org/10.1111/hae.12566
Abstract
Treatment of previously untreated patients (PUPs) with severe haemophilia A is complicated by the formation of inhibitors. Prediction of PUPs with high risk is important to allow altering treatment with the intention to reduce the occurrence of inhibitors. An unselected multicentre cohort of 825 PUPs with severe haemophilia A (FVIII<0.01 IU mL(-1) ) was used. Patients were followed until 50 exposure days (EDs) or inhibitor development. All predictors of the existing prediction model including three new potential predictors were studied using multivariable logistic regression. Model performance was quantified [area under the curve (AUC), calibration plot] and internal validation (bootstrapping) was performed. A nomogram for clinical application was developed. Of the 825 patients, 225 (28%) developed inhibitors. The predictors family history of inhibitors, F8 gene mutation and an interaction variable of dose and number of EDs of intensive treatment were independently associated with inhibitor development. Age and reason for first treatment were not associated with inhibitor development. The AUC was 0.69 (95% CI 0.65-0.72) and calibration was good. An improved prediction model for inhibitor development and a nomogram for clinical use were developed in a cohort of 825 PUPs with severe haemophilia A. Clinical applicability was improved by combining dose and duration of intensive treatment, allowing the assessment of the effects of treatment decisions on inhibitor risk and potentially modify treatment.Keywords
Funding Information
- Baxter International Foundation investigator grant
- Bayer Non-restricted funding
This publication has 27 references indexed in Scilit:
- Reporting and Methods in Clinical Prediction Research: A Systematic ReviewPLoS Medicine, 2012
- F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicityHaemophilia, 2011
- Treatment related factors and inhibitor development in children with severe haemophilia AHaemophilia, 2010
- Clinical issues in inhibitorsHaemophilia, 2010
- Impact of polymorphisms of the major histocompatibility complex class II, interleukin‐10, tumor necrosis factor‐α and cytotoxic T‐lymphocyte antigen‐4 genes on inhibitor development in severe hemophilia AJournal of Thrombosis and Haemostasis, 2009
- Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practiceJournal of Thrombosis and Haemostasis, 2008
- Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia AHaemophilia, 2007
- Environmental risk factors for inhibitor development in children with haemophilia A: a case–control studyBritish Journal of Haematology, 2005
- Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study GroupBlood, 2003
- Low‐dose intermittent factor replacement for post‐operative haemostasis in haemophiliaHaemophilia, 1998